[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600698":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":22,"interventions":44,"overallOfficials":13,"centralContacts":57,"locations":63,"responsibleParty":80,"collaborators":13,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":13,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":13,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":13,"overallStatus":66,"whyStopped":13,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Adicet Therapeutics","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort","This primary endpoint will be used to evaluate safety and tolerability of AD1-001 in subjects with treatment-refractory RA","28 days",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"SINGLE",[21],"PARTICIPANT",[23,30,34,38,41],{"label":24,"type":25,"description":13,"interventionNames":26},"Experimental: Run-in","EXPERIMENTAL",[27,28,29],"Drug: ADI-001","Drug: Fludarabine","Drug: Cyclophosphamide",{"label":31,"type":25,"description":32,"interventionNames":33},"Experimental: Part 1a","Cy\u002FFlu LD",[27,28,29],{"label":35,"type":25,"description":36,"interventionNames":37},"Experimental: Part 1b","Cy-only LD",[27,29],{"label":39,"type":25,"description":32,"interventionNames":40},"Experimental: Part 2a",[27,28,29],{"label":42,"type":25,"description":36,"interventionNames":43},"Experimental: Part 2b",[27,29],[45,50,54],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":13},"DRUG","ADI-001","Anti-CD20 CAR-T",[31,35,39,42,24],{"type":46,"name":51,"description":52,"armGroupLabels":53,"otherNames":13},"Fludarabine","Chemotherapy for Lymphodepletion",[31,39,24],{"type":46,"name":55,"description":52,"armGroupLabels":56,"otherNames":13},"Cyclophosphamide",[31,35,39,42,24],[58],{"name":59,"role":60,"phone":61,"phoneExt":13,"email":62},"Adicet Medical Monitor","CONTACT","021-61673760","lma@shanghaiadicet.cn",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":13,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Adicet Clinical Trials","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":72,"coordinates":73},"Point",[74,75],121.45806,31.22222,{"lat":75,"lon":74},[78],{"name":65,"role":60,"phone":61,"phoneExt":13,"email":79},"yding@shanghaiadicet.cn",{"type":81,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100600698","phase-1-a-phase-1-study-of-adi-001-in-rheumatoid-arthritis-100600698",false,"NCT07100873","A Phase 1 Study of ADI-001 in Rheumatoid Arthritis","A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Treatment-refractory Rheumatoid Arthritis","Inclusion Criteria:\n\n1. ≥ 18 years of age.\n2. Fulfills the 2010 ACR-EULAR RA classification criteria\n3. Agreement not to take traditional medicines and medications not prescribed by a doctor\n4. Adequate hematological, liver, cardiac and pulmonary function\n\nExclusion Criteria:\n\n1. Presence of severe liver disease, Child-Pugh class B or C.\n2. Autoimmune disease requiring prednisone higher than 0.5 mg\u002Fkg\u002Fday (or corticosteroid equivalent).\n3. Subjects unwilling to participate in an extended safety monitoring period (LTFU protocol)\n4. History of a clinically significant infection (including sepsis, pneumonia, bacteremia, fungal, viral and opportunistic infections) within 4 weeks prior to first dose of study drug which in the opinion of the Investigator may compromise the safety of the subject in the study.","ALL","18 Years","80 Years",{"count":93,"type":94},25,"ESTIMATED","INTERVENTIONAL",[97],"PHASE1","ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up",[100],"Rheumatoid Arthritis (RA)","2025-12-01",{"date":103,"type":104},"2025-12-08","ACTUAL",{"date":106,"type":104},"2025-10-10",{"date":108,"type":94},"2028-03-30",{"name":5,"class":6},1]